| [1] |
Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011 [J]. Chin J Cancer Res, 2015, 27 (1): 2-12.
|
| [2] |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013, 63 (1): 11-30.
|
| [3] |
Chen W, Zheng R, Zeng H, et al. The incidence and mortality of major cancers in China, 2012 [J]. Chinese Journal of Cancer, 2016, 35 (1): 73.
|
| [4] |
Bufill JA. Colorectal cancer: evidence for distinct geNETsic categories based on proximal or distal tumor location [J]. Ann Intern Med, 1990, 113 (10): 779-788.
|
| [5] |
Glebov OK, Rodriguez LM, KenNETsh N, et al. Distinguishing right from left colon by the pattern of gene expression [J]. Cancer Epidemiol Biomarkers Prev, 2003, 12 (8): 755-762.
|
| [6] |
Gatot I, Chikman B, Shapira Z, et al. A comparative study of the pathological characteristics of right sided versus left sided colon cancer [J]. Harefuah, 2018, 157(5): 292-295.
|
| [7] |
Song K, Zhao W, Wang W, et al. Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer [J]. Cancer Sci, 2018, 109 (6): 1939-1948.
|
| [8] |
Frank B, Rainer K, Frank M, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival [J]. Diseases of the Colon & Rectum, 2010, 53 (1): 57-64.
|
| [9] |
Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy [J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2013, 31 (29): 3664-3672.
|
| [10] |
Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials [J]. JAMA Oncol, 2017, 3(2): 194-201.
|
| [11] |
Láng I, Köhne CH, Folprecht G, et al. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin [J]. European Journal of Cancer, 2013, 49 (2): 439-448.
|
| [12] |
Hoos A. Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations [J]. Nat Rev Drug Discov, 2016, 15(4): 235-247.
|
| [13] |
Bufill JA. Colorectal cancer: evidence for distinct geNETsic categories based on proximal or distal tumor location [J]. Ann Intern Med, 1990, 113(10): 779-788.
|
| [14] |
Grasso CS, Giannakis M, Wells DK, et al. GeNETsic mechanisms of immune evasion in colorectal cancer [J]. Cancer Discov, 2018, 8 (6): 730-749.
|
| [15] |
Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor [J]. Nature Immunology, 2017, 18 (12): 1332-1341.
|
| [16] |
Ji D, Yi H, Zhang D, et al. Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy [J]. Cancer Immunol Res, 2018, 6 (11): 1401-1416.
|
| [17] |
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition [J]. Nat Rev Immunol, 2013, 13 (4): 227-242.
|
| [18] |
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [J]. Nat Med, 1999, 5(12): 1365-1369.
|
| [19] |
Herbst RS, Soria JC, KowaNETsz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature, 2014, 515(7528): 563-567.
|
| [20] |
Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy [J]. Nat Rev Cancer, 2017, 17(5): 286-301.
|
| [21] |
Asaoka Y, Ijichi H, Koike K. PD-1 blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 373 (20): 1979.
|